granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
market in the country last April. This caused problems for distribution channels of the Company’s customers, as they had to postpone their purchase orders of the Company’s products. As result, domestic
Baht Item Quarter Change (%) H1 Change 2/2017 1/2017 2/2016 1/2017 2/2016 2017 2016 (%) Interest Income Loans 22,166 21,828 21,797 1.5% 1.7% 43,994 44,172 (0.4)% Interbank and money market items 2,045
capital market situation, while fees from bancassurance and mutual fund services increased. Operating Expenses Million Baht Item Quarter Change (%) H1 Change 2/2019 1/2019 2/2018 1/2019 2/2018 2019 2018
, 2017 as follow; Consolidated 3Q/2017 3Q/2016 Change Financial Statements (Million Baht) (%) (Million Baht) (%) (%) Revenue from Sales 1,405.2 100.0 % 1,261.0 100.0 % 11.4 % Cost of Sales (965.8) (68.7
Income Total Revenues (Million Baht) Quarterly Change Six-month End June 30, Change 2/2017 2/2016 % 2017 2016 % Revenue from sales Domestic sales 104.6 117.8 (11.2) 241.4 238.5 1.2 Export sales 391.0
demand in the market. Excess production in China caused extra problems as the local production could not be shipped out due to pandemic, resulting into an intense competition and price in China. For
Management Discussion and Analysis Q3/2019 Financial Result Summary Q3/ 2019 Q3/19 Q3/18 Change +/(-) 9M/19 9M/18 Change +/(-) (in THB mm) YoY 9M Revenue from Sales and Services 57.4 54.3 6% 146.9
DISCUSSION AND ANALYSIS FOR PERIOD ENDED 30 SEPTEMBER 2017 3. Financial highlights (based on Thai FRS) Q3 2017 Financial Position Summary as of 30 September 2017 compared to Q3 2016: Q3 2017 Q3 2016 YoY change
capital market. Going forward, the SEC also focuses on building a sustainable capital market for Thailand.___________________________Remark: * The effective periods may change as specified by the SET.